Back to Journals » Biologics: Targets and Therapy » Volume 7
Treatment and management of myelofibrosis in the era of JAK inhibitors
Authors Keohane C, Radia DH, Harrison CN
Received 31 May 2013
Accepted for publication 16 July 2013
Published 20 August 2013 Volume 2013:7 Pages 189—198
DOI https://doi.org/10.2147/BTT.S34942
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Clodagh Keohane, Deepti H Radia, Claire N Harrison
Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK
Abstract: Myelofibrosis (MF) can present as a primary disorder or evolve from polycythemia vera (PV) or essential thrombocythemia (ET) to post-PV MF or post-ET MF, respectively. MF is characterized by bone marrow fibrosis, splenomegaly, leukoerythroblastosis, extramedullary hematopoiesis, and a collection of debilitating symptoms. Until recently, the therapeutic options for patients with MF consisted of allogeneic hematopoietic stem cell transplant (alloHSCT), the use of cytoreductive agents (ie, hydroxyurea), splenectomy and splenic irradiation for treatment of splenomegaly, and management of anemia with transfusions, erythropoiesis-stimulating agents (ESAs), androgens, and immunomodulatory agents. However, with increased understanding of the pathogenesis of MF resulting from dysregulated Janus kinase (JAK) signaling, new targeted JAK inhibitor therapies, such as ruxolitinib, are now available. The purpose of this article is to review the clinical features of MF, discuss the use and future of JAK inhibitors, reassess when and how to use conventional MF treatments in the context of JAK inhibitors, and provide a perspective on the future of MF treatment.
Keywords: myelofibrosis, ruxolitinib, JAK inhibitor
Corrigendum for this article has been published
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.